#athx

[liddledarkangel]

Missing you, California 🥀

[pknoepfl]

Athersys & Mesoblast stem cell drugs for novel coronavirus disease COVID-19?

2019-nCoV virus pathogenicity was tested in cell culture, with damage to the cells on the right upper corner being visible. Such assays may help devise treatments for COVID-19. Credit: Pasteur Institut Pasteur/CNR for Respiratory Viruses at the Institut Pasteur.

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus?

Stem cells, ARDS, and COVID-19

I’v…

View On WordPress

[abrcapfinancial-blog]

EARNING UPDATE $ATHX Athersys, Inc. for quarter ending q_Jun18 - Revenue grew, Margins expanded

EARNING UPDATE $ATHX Athersys, Inc. for quarter ending q_Jun18 – Revenue grew, Margins expanded

[s2If !current_user_can(access_s2member_level0)]Please login to read the earning update on ATHX [lwa][/s2If][s2If current_user_can(access_s2member_level0)]Athersys, Inc. reported earnings (EPS) of 0.05 per share for the quarter ending q_Jun18. This is vis-vis -0.08 per share for the previous quarter ending q_Mar18, a growth of 162.5 %. Compared to last year same quarter (q_Jun17), earnings grew…

View On WordPress

[lightningtrades-blog]

Morning Watch ! #AXON #ATHX Trade Wisely!

[ustribunenews-blog]

(Nasdaq:ATHX) Athersys, Inc. Breaks 52 Week High Record Of $2.81

(Nasdaq:ATHX) Athersys, Inc. Breaks 52 Week High Record Of $2.81

Athersys, Inc. (Nasdaq:ATHX)

June 5th, 2018

Athersys, Inc. went up $0.08 Sunday, a 2.95% jump, closing at $2.79. In addition it hit a new 52 week high of $2.81. The stock continues to trade well at 116% of its 52 week low of $1.29.

ATHX outperformed the rest of the Healthcare sector which went down 0.15% today.

(more…)

View On WordPress

[ustribunenews-blog]

Athersys, Inc. (Nasdaq:ATHX) Sets 52 Week High Record

Athersys, Inc. (Nasdaq:ATHX) Sets 52 Week High Record

Athersys, Inc. (Nasdaq:ATHX)

June 4th, 2018

Amidst rising markets Athersys, Inc. rose $0.19 Friday, up 7.54%, closing at $2.71. In addition it hit a new 52 week high of $2.78. The stock continues to trade well at 110% of its 52 week low of $1.29. In addition to finishing higher, trading volumes were solid at 299% of normal which can indicate investors see opportunities.

ATHX outperformed…

View On WordPress

[alphabetastock-blog]

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/analysts-strong-buy-on-athersys-nasdaqathx/11620/

Analysts Strong Buy on Athersys (NASDAQ:ATHX)

(adsbygoogle = window.adsbygoogle || []).push();

Athersys, Inc. (NASDAQ:ATHX) has been on a steep run up in price since late 2015. So are analysts still as positive on it even with the current run up in price? We look to see. [Trend Analysis]

Analysis

Athersys, Inc. (NASDAQ:ATHX) last traded at $2.82 after moving down -1.40% for the trading day. The company last released their quarterly earnings results on March 12 for the period ended Dec-14. The company reported earnings of -$0.08 against a Zack’s research estimate of -$0.09. This represents a -11.11% surprise on the expected result.

The current average broker recommendation for Athersys, Inc., according to Zack’s research, is 1.00, based on 3 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see Athersys, Inc. as a strong buy. The 12 month target consensus price estimate among these analysts for Athersys, Inc. is currently at $3.84.

Out of the 3 broker recommendations for ATHX, 3 recommend it as a strong buy, 0 as a buy, 0 as a hold 0 as a sell and 0 as a strong sell.

For the current quarter, the consensus analyst estimate for Athersys, Inc. (NASDAQ:ATHX) is N/A, with analysts expecting year on year growth for the company of N/A

About Athersys, Inc. (NASDAQ:ATHX)

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.